<DOC>
	<DOCNO>NCT02879760</DOCNO>
	<brief_summary>This Phase 1/2 , multi-center , open-label , dose-escalation trial Ad-MAGEA3 MG1-MAGEA3 combination pembrolizumab patient Non-Small Cell Lung Cancer complete first standard therapy platinum base chemotherapy .</brief_summary>
	<brief_title>Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine Combination With Pembrolizumab Non-Small Cell Lung Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>1 . Have histologically cytologically confirm diagnosis NSCLC ( squamous nonsquamous ) positive expression MAGEA3 ( primary metastatic lesion ) . 2 . Have radiographic progression treatment least 1 cycle platinumdoublet chemotherapy . Adjuvant therapy count regimen administer within 1 year relapse . 3 . Patients tumor nonsquamous NSCLC histology know epidermal growth factor receptor ( EGFR ) mutation and/or anaplastic lymphoma kinase ( ALK ) translocation participate study fail appropriate tyrosine kinase inhibitor ( TKI ) ( intolerance document progression NSCLC ) document progression NSCLC platinum doublet chemotherapy . There preferred order treatment TKI platinum doublet therapy . If patient find one molecular alteration ( either sensitize EGFR mutation ALK translocation ) , test alteration require . 4 . Have measurable disease base RECIST v1.1 criterion determine site study team . Tumor lesion situate previously irradiate area consider measurable progression demonstrate lesion . 5 . Have least one tumor amenable biopsy . 6 . Have Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 7 . Demonstrate adequate organ function : 1 . White blood cell ( WBC ) count ≥3,000 cells/mm3 2 . Absolute neutrophil count ( ANC ) ≥1,500 cells/mm3 3 . Hemoglobin ≥9 g/dL ≥5.6 mmol/L 4 . Platelet count ≥100,000 platelets/mm3 5 . Total bilirubin ≤1.5 x upper limit normal ( ULN ) OR direct bilirubin ≤ULN patient total bilirubin level &gt; 1.5 x ULN 6 . Aspartate transaminase ( AST ) , alanine aminotransferase ( ALT ) ≤2.5 x ULN ; ≤5.0 x ULN patient liver metastases 7 . Serum chemistries sodium , potassium , calcium within normal limit ( WNL ) Grade 1 8 . Serum creatinine ≤1.5 x ULN creatinine clearance ≥60 mL/min patient creatinine level &gt; 1.5 institutional ULN accord CockcroftGault formula 9 . Serum phosphate &gt; 0.8 mmol/L ( Grade 01 ) 10. International normalize ratio ( INR ) ≤1.5 x ULN unless patient receive anticoagulant therapy long prothrombin time ( PT ) partial prothrombin time ( PTT ) within therapeutic range intend use anticoagulant 11 . Activated partial thromboplastin time ( aPTT ) ≤1.5 x ULN unless patient receive anticoagulant therapy long PT PTT within therapeutic range intend use anticoagulant 8 . Female patient childbearing potential must negative urine serum pregnancy test within 72 hour prior receive first dose study medication . If urine test positive confirm negative , serum pregnancy test require . 9 . Female patient childbearing potential ( refer Section 9.E.2.c ) must willing use adequate method contraception outline Section 9.E.2.c , course study 120 day last dose study medication . Note : Abstinence acceptable usual lifestyle preferred contraception patient . 10 . Male patient reproductive potential ( Section 9.E.2.c ) must agree use adequate method contraception outline Section 9.E.2.c , start first dose study therapy 120 day last dose study therapy . Note : Abstinence acceptable usual lifestyle preferred contraception patient . 11 . Be willing able provide write informed consent trial . 12 . Be 18 year age ( legal age majority jurisdiction ) day sign informed consent . 1 . Has disease suitable local therapy administer curative intent . 2 . Has prior treatment anticancer immunotherapy , include therapy antiPD1 , antiPDL1 , antiPDL2 agent previously participate Merck MK3475 clinical trial prior treatment AdMAGEA3 , MG1MAGEA3 , MAGEA3 target therapy . 3 . Is currently receive study therapy participate study investigational agent receive study therapy use investigational device within 4 week Day 1 dose treatment . 4 . Has prior anticancer monoclonal antibody ( mAb ) therapy within 4 week prior study Day 1 failure recover ( i.e. , ≤ Grade 1 baseline status ) adverse event ( AEs ) due agent administer 4 week earlier . 5 . Has prior chemotherapy , target small molecule therapy , radiation therapy within 4 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline status ) AEs due previously administer agent . Note : Patients ≤Grade 2 neuropathy ≤Grade 2 alopecia exception criterion may qualify study . Note : If patient receive major surgery , must recover adequately toxicity and/or complication intervention prior start therapy . Note : Patients receive prior radiation must recover acute toxic effect unless Grade 1 , irreversible consider clinically significant . Note : Patients receive prior lung radiation dose &gt; 30 Gy must wait least 26 week date completion lung radiation first dose pembrolizumab . 6 . Has receive prior treatment vesicular stomatitis virus ( VSV ) base viral vector . 7 . Requires use antiplatelet anticoagulant therapy safely suspend per protocol biopsy per standard care . 8 . Has know active central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Note : Patients previously treat brain metastasis may participate provide stable ( without evidence progression image [ use identical imaging modality assessment , either magnetic resonance imaging ( MRI ) CT scan ] least 4 week prior first dose trial treatment neurologic symptom return baseline ) , evidence new enlarge brain metastasis , use steroid least 28 day prior trial treatment . This exception include carcinomatous meningitis exclude regardless clinical stability . 9 . Has disease/tumor invade major vascular structure ( e.g. , carotid artery ) , tumor relate impend bowel obstruction clinically significant and/or rapidly accumulate ascites , pericardial pleural effusion . 10 . Has active autoimmune disease require systemic treatment past 2 year ( i.e. , use disease modify agent , corticosteroid immunosuppressive drug ) . Replacement therapy ( e.g. , thyroxine , insulin , physiologic corticosteroid replacement therapy adrenal pituitary insufficiency , etc . ) consider form systemic treatment . 11 . Has evidence active , noninfectious pneumonitis . 12 . Has history interstitial lung disease . 13 . Has active infection require systemic therapy . 14 . Has know active Hepatitis B ( e.g. , HBsAg reactive ) Hepatitis C ( e.g. , HCV RNA [ qualitative ] detect ) . 15 . Has use antiviral medication , within 14 day enrollment . 16 . Has condition likely result splenic dysfunction ( e.g. , splenectomy , sickle cell anemia , radiation spleen &gt; 20 Gy , congenital asplenism ) . 17 . Has significant immunodeficiency due underlie illness ( e.g. , known HIV/AIDS ) and/or medication ( e.g. , systemic corticosteroid ) use immunosuppressive therapy within 4 week prior first dose trial treatment . Note : Patients must receive dos &gt; 10 mg/day prednisone equivalent time study entry corticosteroid may use premedication . 18 . Has uncontrolled preexist cardiovascular condition and/or symptomatic cardiac dysfunction . 19 . Has &gt; Grade 2 dyspnea and/or requirement supplemental oxygen . 20 . Has receive live vaccine within 30 day plan start study therapy ( Note : kill flu vaccine acceptable ) . 22 . Has know additional malignancy progress require active treatment . Exceptions include basal cell carcinoma skin , squamous cell carcinoma skin undergone potentially curative therapy situ cervical cancer . 22 . Has history current evidence condition , therapy , laboratory abnormality might confound result trial , interfere patient 's participation full duration trial , best interest patient participate , opinion treat investigator . 23 . Has know psychiatric substance abuse disorder would interfere cooperation requirement trial . 24 . Is pregnant breastfeeding , expect conceive father child within project duration trial , start screen visit 120 day last dose trial treatment . 25 . Has household contact meet follow criterion study entry unless alternate living arrangement make : . Women pregnant nursing infant b . Children &lt; 12 month age c. Individuals severely immunocompromised ( include limit bonemarrow organ transplant recipient ; individual Human Immunodeficiency virus { HIV } infection ; individual receive chronic immunosuppressive medication ) . 26 . Is immediate family member ( e.g. , spouse , parent/legal guardian , sibling child ) investigational site Sponsor staff directly involve trial , unless prospective Research Ethics Board approval ( chair designee ) give allow exception criterion specific patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Lung</keyword>
	<keyword>Cancer</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Oncolytic virus</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Pembrolizumab</keyword>
	<keyword>Keytruda</keyword>
</DOC>